Daniel Orlovich, M.D., PHARM. D.
Pharmacist in Van Nuys, California. This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 290,447 in Pharmacist, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
What the federal data shows
Daniel Orlovich, M.D., PHARM. D. reported a CMS MIPS final score of 77.6/100 - below the 83.1 national average - and filed 859 Medicare Part D claims in 2023.
- 77.6/100
- MIPS score · -6 vs avg
- 859
- Part D claims, 2023
- $561.8
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Daniel Orlovich, M.D., PHARM. D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
78 24th percentile higher than 24% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Daniel Orlovich, M.D., PHARM. D. sits
This provider among pharmacist peers
Across the 37 pharmacist providers who report both Medicare Part D prescribing and a MIPS quality score, Daniel Orlovich, M.D., PHARM. D. writes more Part D claims than 59% of them and scores higher on MIPS quality than 24% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one pharmacist peer from a representative sample of 36; the gold marker is Daniel Orlovich, M.D., PHARM. D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
What does the federal data show about Daniel Orlovich, M.D., PHARM. D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in California
How Pharmacist compares to other specialties among California providers
Largest specialties in California (% of in-state providers)
Pharmacist ranks #5 among California's specialties (3.5% of in-state providers)
Each bar is a specialty's share of the California provider total, by primary NUCC taxonomy. The highlighted bar is Pharmacist; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Daniel Orlovich, M.D., PHARM. D.'s 2023 MIPS final score plotted against the Pharmacist national average
- MIPS Final Score
- 77.6/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Pharmacist) - 77.6/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Pharmacist US NPIs
77.6/100 MIPS final score - 5.5 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Pharmacist. Quality dim: 80.2. Cost dim: 45.1.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Daniel Orlovich, M.D., PHARM. D. appears in the CMS NPPES registry as a Pharmacist provider holding M.D., PHARM. D. credentials at 6815 NOBLE AVE, Van Nuys, CA, 91405, with a listed phone of (818) 901-6600. NPI 1891072070 was issued on 11/15/2011. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what Orlovich most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 859 prescription claims written by this provider, covering 257 Medicare beneficiaries and totaling roughly $12K in drug spend, with an opioid prescribing rate of 9.1%. These figures capture only Medicare Part D, commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 77.6/100 for the 2023 performance year (Quality 80.2, Cost 45.1), compared with the national average of 83.1.
Pharmacist is a high-volume specialty nationwide, with 290,447 enrolled providers across 56 states and an average of 135 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1891072070 |
|---|---|
| Specialty | Pharmacist |
| Credentials | M.D., PHARM. D. |
| Gender | Male |
| NPI Issued | 11/15/2011 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Daniel Orlovich, M.D., PHARM. D.'s current license status, disciplinary history, and board certifications with the Medical Board of California in California before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Daniel Orlovich, M.D., PHARM. D.. Source: openpaymentsdata.cms.gov.
Total received
$562
Largest payer
Abbott Laboratories
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Daniel Orlovich, M.D., PHARM. D.. To verify Daniel Orlovich, M.D., PHARM. D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 982
- Total Day Supply
- 26,221
- Generic Drug Cost
- $12K
- Opioid Claims
- 78 (9.1% rate)
- Antibiotic Claims
- 26
Patient Demographics
- Average Patient Age
- 73.0 years
- Avg HCC Risk Score
- 1.05
- Gender Split
- 60% female / 40% male
- Age Distribution
- <65: 20, 65-74: 130, 75-84: 90, 85+: 17
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Daniel Orlovich, M.D., PHARM. D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Gabapentin
Gabapentin
249 claims
- Meloxicam
Meloxicam
142 claims
- Duloxetine Hcl 77
Duloxetine Hcl
77 claims
- Methylprednisolone 44
Methylprednisolone
44 claims
- Tizanidine Hcl 44
Tizanidine Hcl
44 claims
- Pregabalin 40
Pregabalin
40 claims
- Tramadol Hcl 37
Tramadol Hcl
37 claims
- Diclofenac Sodium 30
Diclofenac Sodium
30 claims
| Drug | Claims |
|---|---|
| Gabapentin | 249 |
| Meloxicam | 142 |
| Duloxetine Hcl | 77 |
| Methylprednisolone | 44 |
| Tizanidine Hcl | 44 |
| Pregabalin | 40 |
| Tramadol Hcl | 37 |
| Diclofenac Sodium | 30 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 24 |
| Cyclobenzaprine Hcl | 21 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pharmacist Overview
How Daniel Orlovich, M.D., PHARM. D. fits within the Pharmacist landscape nationally.
Daniel Orlovich, M.D., PHARM. D.'s 859 claims are above the specialty average of 135.
Nearby Pharmacist Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Orlovich.
Compare Pharmacist nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Pharmacist peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore California
Frequently Asked Questions
What is Daniel Orlovich, M.D., PHARM. D.'s specialty? ▼
How much does Daniel Orlovich, M.D., PHARM. D. prescribe under Medicare Part D? ▼
What is Daniel Orlovich, M.D., PHARM. D.'s Medicare quality score? ▼
Where is Daniel Orlovich, M.D., PHARM. D. located? ▼
What is Daniel Orlovich, M.D., PHARM. D.'s NPI number? ▼
Does Daniel Orlovich, M.D., PHARM. D. prescribe opioids? ▼
How many Pharmacist providers are there in the US? ▼
What drugs does Daniel Orlovich, M.D., PHARM. D. prescribe most often? ▼
Does Daniel Orlovich, M.D., PHARM. D. accept Medicare? ▼
How can I verify Daniel Orlovich, M.D., PHARM. D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology